Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 15;14(1):2047144. doi: 10.1080/19420862.2022.2047144

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This work was authored as part of the Contributor’s official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 U.S.C. 105, no copyright protection is available for such works under U.S. Law.

This is an Open Access article that has been identified as being free of known restrictions under copyright law, including all related and neighbouring rights (https://creativecommons.org/publicdomain/mark/1.0/). You can copy, modify, distribute and perform the work, even for commercial purposes, all without asking permission.

PMC Copyright notice

Figure 5. — NIH-CoVnb-112 nebulization treatment in a hamster model of SARS-CoV-2. (a) Schematic overview of study design for nebulization treatment of Syrian hamsters with NIH-CoVnb-112. Adult Syrian hamsters (n = 8/group, males, 12 weeks old) were treated at −24 hours prior to virus challenge with nebulized saline or NIH-CoVnb-112 (25 mg/mL) in a 5 mL volume over 20 minutes. Following intranasal challenge, each group was treated at 12 hours post infection with the same condition, and again at 1 dpi. Half of the animals in each group received a fourth dose at 2 dpi. Animals were weighed daily and oral swabs taken at dpi 1–3. Groups were euthanized at day 3 and day 7 post infection respectively and sample taken for assessment. (Figure elements generated using BioRender.com) (b) Body weight change as a percentage of baseline weight for day 7 post infection group (n = 4/group, mean ± SD) (c) Viral burden from turbinate tissue of the day 7 post infection group as determined by double plaque overlay assay. (d) Viral burden from cranial lung tissue of the day 7 post infection group as determined by double plaque overlay assay. (e-f) Hematoxylin and eosin-stained tissue sections from the day 3 and day 7 post infection animals were semi-quantitively scored by a pathologist blinded to condition using an established scoring metric. Metrics included overall lesion extent, bronchitis, alveolitis, pneumocyte hyperplasia, vasculitis, and interstitial inflammation; each on a 0–4 (lesion extent) or 0–5 scale (all others) and scores summed for both lungs. Detailed data for day 3 and day 7 post infection are shown in Supplementary Fig. 10.